{
    "clinical_study": {
        "@rank": "31731", 
        "arm_group": [
            {
                "arm_group_label": "A/17/turkey/Turkey/05/133 (H5N2)", 
                "arm_group_type": "Experimental", 
                "description": "150 participants (100 vaccinees and 50 placebos) will be admitted in the isolation ward for 5 days after each immunization mainly for safety assessment. Two doses of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2)or placebo will be given by intranasal route 28 days apart and will be followed for the total of 60 days."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate immune response and safety of live attenuated\n      influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) manufactured by GPO,\n      Thailand in healthy Thais."
        }, 
        "brief_title": "Safety and Immunogenicity of Live Attenuated Influenza H5N2", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Influenza Due to Influenza A Virus Subtype H5N2", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "detailed_description": {
            "textblock": "It is a double blind randomized study using 7.5-8.5 log EID50 dose which is the same dose as\n      being tested in phase I.\n\n      150 participants (100 vaccinees and 50 placebos) age 18-49 years old will be enrolled. All\n      will be separated in 4 batches; Batch 1: 36 participants (24 vaccinees and 12 placebos)\n      Batch 2: 38 participants (25 vaccinees and 13 placebos) Batch 3: 38 participants (25\n      vaccinees and 13 placebos) Batch 4: 38 participants (26 vaccinees and 12 placebos)\n\n      Each batch will be admitted in the isolation ward for 5 days after each immunization mainly\n      for safety assessment. Two doses of live attenuated influenza H5 vaccine candidate strain\n      A/17/turkey/Turkey/05/133 (H5N2) will be given by intranasal route 28 days apart. Total\n      follow up is 60 day."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy\n\n          -  Age 18-49  years old\n\n          -  Having Thai ID  card or equivalent\n\n          -  Are seronegative to the specific H5 influenza virus determined by antibody titer less\n             than 1:40 by HAI test to the corresponding antigen.\n\n          -  Anti HIV - Negative\n\n          -  All hematology,  biochemistry and urine analysis are  within normal range or of no\n             clinical significance (not more than 1.5 times of normal value)\n\n          -  Able to read and write and sign written informed consent.\n\n        Exclusion Criteria:\n\n          -  Known history of egg allergy\n\n          -  Having had recently influenza infection confirmed as H5\n\n          -  History of bronchial asthma\n\n          -  History of chronic lung diseases\n\n          -  History of chronic rhinitis\n\n          -  History of immunodeficiency state\n\n          -  History of immunosuppression\n\n          -  History of heavy smoking (more than 5 rolls per day)\n\n          -  History of alcoholic (pure drink 200 ml per day)\n\n          -  Acute infectious and noninfectious diseases (within 2 weeks)\n\n          -  Exacerbation of chronic diseases or cancer or HIV positives\n\n          -  Anamnestic leukocytosis, hepatitis B and C positives\n\n          -  The volunteers who have been taking immunoglobulin products or have had a blood\n             transfusion during past three months before the beginning of the experiment\n\n          -  Participation in other research study or stop participant less than 1 month\n\n          -  Pregnancy or plan to become pregnant for 60 days after enrollment or breast feeding\n\n          -  Any concomitant medication with Aspirin\n\n          -  Poultry workers"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "49 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01841918", 
            "org_study_id": "GPO AVIAN FLU Vaccine-V02-2"
        }, 
        "intervention": {
            "arm_group_label": "A/17/turkey/Turkey/05/133 (H5N2)", 
            "intervention_name": "Avian Flu Vaccine", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 18, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bangkok", 
                    "country": "Thailand", 
                    "zip": "10400"
                }, 
                "name": "Faculty of Tropical Medicine"
            }
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Thailand: Ethical Committee", 
                "Thailand: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Phase II safety and immunogenicity of live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 (H5N2) in healthy Thai volunteers", 
            "safety_issue": "Yes", 
            "time_frame": "within 60 days after screening"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01841918"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mahidol University", 
            "investigator_full_name": "Punnee Pitisuttithum", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mahidol University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "The Government Pharmaceutical Organization", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "World Health Organization", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Mahidol University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}